EWA
SVA

EverSource Wealth Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

EverSource Wealth Advisors’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4
Closed – – 3163
2024
Q2 		$0 Hold
4
– – ﹤0.01% 3188
2024
Q1 		$0 Buy
+4
New – ﹤0.01% 3038
2023
Q4 		– Sell
-4
Closed – – 2794
2023
Q3 		$0 Hold
4
– – ﹤0.01% 2714
2023
Q2 		$0 Buy
+4
New – ﹤0.01% 2650

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return

EverSource Wealth Advisors's SVA Position: Q3 2024 in Review

EverSource Wealth Advisors sold out of Sinovac Biotech, Ltd (SVA) in Q3 2024, closing a stake of 4 shares.

EverSource Wealth Advisors first reported a position in SVA in Q2 2023 and held it in 4 quarters. The position peaked at $0 in Q2 2024. 9 funds tracked by Wall St. Rank hold SVA as of Q3 2024.

  • EverSource Wealth Advisors reported no remaining Sinovac Biotech, Ltd position as of Q3 2024 after selling out during the quarter.
  • EverSource Wealth Advisors sold 4 Sinovac Biotech, Ltd shares in Q3 2024.
  • EverSource Wealth Advisors first reported a position in Sinovac Biotech, Ltd in Q2 2023 and held it in 4 quarters.
  • EverSource Wealth Advisors's Sinovac Biotech, Ltd position peaked at $0 in Q2 2024.
  • 9 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2024.

Based on EverSource Wealth Advisors's 13F filing for Q3 2024, filed 8 Nov 2024.